Please assess the completion status of the following clinical trial:

Trial Title: Cyclosporine Plus Methotrexate or Alemtuzumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Having an identical Human Leukocyte Antigens (HLA) or a mismatched family donor.~2. Age between 45 and 65 years (outside this age range at the discretion of each center).~3. Indications:~   * Follicular lymphoma with one of the following characteristics:~     1. Poor prognosis follicular NHL (3 or more factors by Federico et al: erythrocyte sedimentation rate (ESR)\> 30, male,\> 60 years, high LDH\> 2 extranodal areas, pathologic stage (PS) \>2 or The International Prognostic Index (IPI) 3 or high lactate dehydrogenase (LDH) or micro Beta 2) failing to achieve CR with regimens including fludarabine and anti CD20 (cluster of differentiation antigen 20 ).~    2. 2nd CR (complete response) or PR (partial response) not candidates for autologous transplantation;~    3. persistent disease or relapse after autologous transplantation.~  * Other low-grade lymphomas:~     1. relapsed after autologous transplantation.~    2. autologous transplant candidates which can not be performed because of the inability to collect a sufficient number of cells, steam cells disease persistence, etc..~  * Chronic lymphocytic leukemia with one of the following characteristics:~     1. B symptoms: weight loss \>10% in the last 6 months, fever \>38ºC (degrees centigrade) for 14 days without infection, night sweats without infection~    2. lymphadenopathy \>10 cm or progressive, progressive splenomegaly~    3. Anemia and/or thrombocytopenia secondary to bone marrow infiltration~    4. Diffuse lymphocytic infiltration of the bone marrow~    5. Progressive lymphocytosis (\>50% in 2 months) or a lymphocyte doubling time \<12 months Any of the above criteria is an inclusion criteria in the protocol in patients who have received at least one line of treatment including fludarabine~    6. Patients with poor prognostic cytogenetic abnormalities: 17p-, 11q-with VDJ unmutated~4. Patients must also meet the following general requirements:~   1. Performance status \<3 (Zubrod score, Eastern Cooperative Oncology Group (ECOG) performance status or WHO (World Health Organization) )~  2. forced expiratory volume at one second (FEV1) \> 39%, lung diffusing capacity for carbon monoxide (DLCO) and forced vital capacity (FVC) \> 39% of the theoretical values~  3. Total bilirubin and transaminases \<3 x the normal maximum value, unless attributable to base haemopathy~  4. Creatinine \<2 x normal maximum and clearance\> 40 mL / min unless attributable to his base haemopathy~  5. No evidence of symptomatic disease, cirrhosis or active hepatitis~  6. Negative serology for HIV~  7. Written informed consent~Exclusion criteria:~1. Impaired hepatic or renal function superior to that described above~2. Presence of serious diseases that prevent chemotherapy treatments~3. Presence of psychiatric comorbidity~4. HIV infection~5. Other prior neoplasm~6. Do not have signed informed consent~7. Pregnant or at risk of pregnancy by inadequate contraceptive measures.~8. Patients diagnosed with chronic lymphocytic leukemia (CLL) transformation to more aggressive cytologic or histologic forms (prolymphocytic leukemia, large cell lymphoma, Hodgkin's disease) and those affected with autoimmune hemolytic anemia

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporine + METHOTREXATE (Type: ACTIVE_COMPARATOR): MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
- Cyclosporine + CAMPATH-1H (Type: EXPERIMENTAL): CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.

Based on this trial design, predict the completion outcome and termination type (if applicable).